REFERENCES
- Shapiro L, Knowles S, Shear N. Drug interactions of clinical significance for the dermatologist: recognition and avoidance. Am J Clin Dermatol 2003; 4(9): 623–639.
- Singer MI, Shapiro LE, Shear NH. Cytochrome P-450 3A: interactions with dermatologic therapies. J Am Acad Dermatol 1997; 37(5 Pt 1):765–771.
- Ahmad N, Mukhtar H. Cytochrome p450: a target for drug development for skin diseases. J Invest Dermatol 2004; 123(3): 417–425.
- Gonzales FJ. The molecular biology of cytochrome P450s. Pharmacol Rev 1989; 40: 243–288.
- Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994; 26(2): 144–160.
- Bickers DR, Kappas A. Human skin aryl hydrocarbon hydroxylase-induction by coal tar. J Clin Invest 1978; 62:1061.
- Slaughter RL, Edwards DJ. Recent advances: The cytochrome P450 enzymes. Ann Pharmacother 1995; 29: 619–624.
- Andersen WK, Feingold DS. Adverse drug interactions clinically important for the dermatologist. Arch Dermatol 1995; 131: 468–473.
- Ameen M, Smith CH, Barker JN. Pharmacogenetics in clinical dermatology. Br J Dermatol 2002; 146(1): 2–6.
- Nebert DW. Polymorphisms in drug-metabolising enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 1997; 60:265–271.
- Meggit SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomized controlled trial. Lancet 2006; 367: 839–846.
- Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32(3): 210–258.
- Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20(8): 342–349.
- Cross J, Lee H, Westelinck A, Nelson J, Grudzinskas C, Peck C. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980–1999. Pharmacoepidemiol Drug Saf 2002; 11(6): 439–446.
- Heerdink ER, Urquhart J, Leufkens HG. Changes in prescribed drug doses after market introduction. Pharmacoepidemiol Drug Saf 2002; 11(6): 447–453.
- WHO Collaborating Centre for Drug Statistics Methodology (2006) About the ATC/DDD system. http://www.whocc.no/atcddd/ (accessed July 2006).
- Stolk P, Heerdink ER, Leufkens HGM. Changes in the defined daily dose; CYP2D6/CYP3A metabolism as an indicator for dose-setting problems. Eur J Clin Pharmacol 2005; 61(3): 243–246.
- Bluhm RE, Adedoyin A, McCarver DG, Branch RA. Development of dapsone toxicity in patients with inflammatory dermatoses: Activity of acetylation and hydroxylation of dapsone as risk factors. Clin Pharmacol Ther 1999; 65(6): 598–605.
- Wakelin SH, Maibach HI, eds. Systemic Drug Treatment in Dermatology; London, UK: Manson Publishing, 2004.
- DrugBank (2006). http://redpoll.pharmacy.ualberta.ca/drugbank/index.html (accessed July 2006).
- Dockx P, Decree J, Degreef H. Inhibition of endogenous retinoic acid as treatment for severe psoriasis: An open study with oral liarozole. Br J Dermatol 1995; 133: 426–432.
- Kira M, Kobayashi T, Yoshikawa K. Vitamin D and the skin. J Dermatol 2003; 30: 429–437.
- Kang S, Li XY, Duell EA, Voorhees JJ. The retinoid X receptor agonist 9-cis-retinoic acid and the 24-hydroxylase inhibitor ketoconazole increase activity of 1,25-dihydroxyvitamin D3 in human skin in vivo. J Invest Dermatol 1997; 108(4):513–518.
- Smith G, Wolf CR, Deeni YY, Dawe RS, Evans AT, Comrie MM, Ferguson J, Ibbotson SH. Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet 2003; 361(9366): 1336–1343.